TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Days to Next Herpes Labialis Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Liking/effect score of the e-cigarette
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dynamic lung compliance measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dexa measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip Strength in the More Affected Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guy's Neurologic Disability Scale (GNDS) for Upper Limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of disordered BBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion Measured by HI Antibody Response on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroprotection Measured by HI Antibody Response on Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proellex peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proellex time to peak plasma concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery at three month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjusted geometric means of area under the serum concentration-time curve (AUC(0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean max improvement in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to onset of max improvement in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean number of vacuole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean vacuolar area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of C-Tb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical safety of C-Tb
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving the second Autologous Stem Cell Transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gait single stance time asymmetry and duration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait paretic double support/single stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stepping weight transfer time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stepping knee angular displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stepping peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lesion Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in time to ON after first morning dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urodynamic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum Testosterone (Total)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Erectile Function (EF) domain score of IIEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom rate of atrial tachy-arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) based on toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinical malaria in Year 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intensity and quality of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weekly Change in Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Independence After 6 Months of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With HbA1c < 6.0 % After 6 Months of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Fasting Plasma Glucose (FPG) < 7 mmol/l After 6 Months of Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lumbar Multifidus muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of exclusivity of breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfer to ICU or Unexpected Death Within 24 Hrs
Endpoint domain: Mortality/survival
Primary endpoint: cure rate of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in subthreshold psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fasting Insulin Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain score immediately after washing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return Visit to the ED Within 30 Days of ED Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SPEED Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MGMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Necrotic Core volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of desensitization measured by oral food challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac death, myocardial infarction, or stent thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Physical Performance Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient completion rates for CFI-EA intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient scores on the CSQ-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Global Impressions Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volume MR parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1 MR parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion weighted imaging MR parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum blood pressure during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of SBP increase by 30% or more from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum HR during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fugl-Meyer motor function score of lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insulin secretion during clamp test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of Participants Who Accepted and Completed 3HP
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Active but tolerable sublingual dose of Salvinorin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD contrast signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local cerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Contrast sensitivity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Dopamine Transporter availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical outcome of the pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Self Selected Velocity on Treadmill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot Trajectory Range (Toe Off to Heel Strike)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propulsive Impulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Nexavar treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neutrophil response to ultraviolet radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in inflammasome response to ultraviolet radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in O'Leary-Sant Interstitial Cystitis Problem Index Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ventral passes of the spinal needle into the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful performance of real-time ultrasound guided spinal needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Test-retest reliability of cognitive assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery-Åsberg depression rating scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in Patient Reported PRO-CTCAE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intravenous fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcome (FAAM-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Brain perfusion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG source imaging assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Sitting Diastolic Blood Pressure (SiDBP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Sitting Systolic Blood Pressure (SiSBP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average Daily Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in the Individualised Care Scale score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Quality of Care Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC and Cmax of sildenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Nerve Stimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial infarction and cerebrovascular accidents
Endpoint domain: Mortality/survival
Primary endpoint: Death within 30 days of implantation
Endpoint domain: Mortality/survival
Primary endpoint: Quality of the oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality perifollicular doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hr Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected monocular high contrast Near VA of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of menstrual pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression anxiety stress scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of Implemented Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Implemented Interventions
Endpoint domain: Adverse events/effects
Primary endpoint: Need for Cesarean Delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients with pulmonary embolism
Endpoint domain: Mortality/survival
Primary endpoint: IPV Intervention Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPV Intervention Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IPV Intervention Safety
Endpoint domain: Adverse events/effects
Primary endpoint: General Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Heart Failure Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Strain ratio comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the Leicester Cough Questionnaire (LCQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change in FEV1 at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute Change in SGRQ Score at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacokinetic Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of the moderate to severe anterior deep bite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of overjet and overbite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arch length to incised edge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of depsipeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transepidermal Water Loss (TEWL) on Sacrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Transepidermal Water Loss (TEWL) on Heel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: POP-Q Ba point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on Motor Functioning Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appetite Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Achieved Sitting Alone for at Least 30 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Standing Alone for at Least 3 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of sodium fluorescein dye in the anterior chamber
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: antiviral effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age at First Successful Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance of bleeding
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of terminal patients in the ICU
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in Global Improvement Score (GIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Best Overall Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful wound healing for at least two consecutive measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety/tolerability of repeat oral doses of darapladib
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Pharmacokinetic parameters of repeat oral doses of darapladib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary Gland Maximal Standardized Uptake Values (SULmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Experiencing Significant Change on a 4 Point Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical dimensions of the alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (All-Causality)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Aripriprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Infinity (AUC Infinity) of Aripiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Dehydro-Aripiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Infinity (AUC Infinity) of Dehydro-Aripiprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copies numbers of CAR in peripheral blood and/or bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Nepean Dyspepsia Life Quality Index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Iron metabolism differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve for insulin and glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain responses to early visual and auditory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: uncontrolled leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tasimelteon pharmacokinetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of agreement between interpretations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Prognostic Markers of Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of PrEP-OI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Probing Depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Keratinized Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes